Research Publication: CAR-T Cells Are Serial Killers

A recent publication by A J Davenport et al in Cancer Immunology Research demonstrates the "serial killing" nature of individual CAR cells by killing multiple tumor cells. Killing assays were performed using xCELLigence.

CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells

Alexander J. Davenport, Misty R. Jenkins, Ryan S. Cross, Carmen S. Yong,
H. Miles Prince, David S. Ritchie, Joseph A. Trapani, Michael H. Kershaw,
Phillip K. Darcy, and Paul J. Neeson

Adoptive therapy with chimeric antigen receptor (CAR) T cells shows great promise clinically. However, there are important aspects of CAR-T-cell biology that have not been explored, particularly with respect to the kinetics of activation, immune synapse formation, and tumor cell killing. Moreover, the effects of signaling via the endogenous T-cell receptor (TCR) or CAR on killing kinetics are unclear. To address these issues, we developed a novel transgenic mouse (designated CAR.OT-I), in which CD8+ T cells coexpressed the clonogenic OT-I TCR, recognizing the H-2Kb–presented ovalbumin peptide SIINFEKL, and an scFv specific for human HER2. Primed CAR.OT-I T cells were mixed with SIINFEKL-pulsed or HER2-expressing tumor cells and visualized in real-time using time-lapse microscopy. We found that engagement via CAR or TCR did not affect cell death kinetics, except that the time from degranulation to CAR-T-cell detachment was faster when CAR was engaged. We showed, for the first time, that individual CAR.OT-I cells can kill multiple tumor cells (“serial killing”), irrespective of the mode of recognition. At low effector:target ratios, the tumor cell killing rate was similar via TCR or CAR ligation over the first 20 hours of coincubation. However, from 20 to 50 hours, tumor cell death mediated through CAR became attenuated due to CAR downregulation throughout the time course. Our study provides important insights into CAR-T–tumor cell interactions, with implications for single- or dual receptor–focused T-cell therapy. Cancer Immunol Res; 3(5); 483–94. ©2015 AACR.

xCELLigence & CAR-T cytotoxic screening: Find out More! ols-bio.de/car-t

 
 

Passende Artikel

xCELLigence SP

Space saving 96-well Single-Plate System xCelligence SP: Single plate system for 96-well E-Plates. Small foot print, minimum space consumption inside the incubator. Run your Real Time Cell Analysis (RTCA) fully automated and label-free to produce data of highest quality and integrity. A broad application range and full kinetic data recorded make this technology far superior to any conventional assays. Get a wealth of information on the...

Preis auf Anfrage

2801000

xCELLigence MP

The highly flexible System for High Throughput and/or Multi User Applications xCELLigence MP: Multi-Plate system for 6 x 96-well E-Plates. Highest flexibility for labs with really high sample throughput, or simultaneous use by several different users. Run your Real Time Cell Analysis (RTCA) fully automated and label-free to produce data of highest quality and integrity. The software covers a broad application range and incorporates a very...

Preis auf Anfrage

2801003

 
 

Kommentar schreiben

 

Die mit einem * markierten Felder sind Pflichtfelder.